UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 24, 2017
NEOGEN CORPORATION
(Exact name of registrant as specified in its charter)
MICHIGAN | 0-17988 | 38-2367843 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
620 Lesher Place Lansing, Michigan | 48912 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code 517-372-9200
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events |
On January 24, 2017, Neogen Corporation announced that it had terminated its agreement with SenesTech Incorporated (NASDAQ: SNES) related to the manufacturing and marketing of a rodenticide being developed by SenesTech. A copy of the press release is attached as Exhibit 99.1 to this report.
This Form 8-K and the attached exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
99.1 | Neogen Corporation Press Release dated January 24, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEOGEN CORPORATION | ||||||
(Registrant) | ||||||
Date: January 24, 2017 | ||||||
/s/ Steven J. Quinlan | ||||||
Steven J. Quinlan | ||||||
Vice President & CFO |
Exhibit 99.1
FOR IMMEDIATE RELEASE
CONTACT: | Steven J. Quinlan |
Neogen Vice President & CFO |
517/372-9200 |
Neogen announces SenesTech agreement cancellation
LANSING, Mich., Jan. 24, 2017 Neogen Corporation (NASDAQ: NEOG) announced today that it had terminated its agreement with SenesTech Incorporated (NASDAQ: SNES) related to the manufacturing and marketing of a rodenticide being developed by SenesTech. The two firms had worked together since 2014 prior to the time when the SenesTech product was approved by the U.S. Environmental Protection Agency.
The final EPA approval provided that the product could only be used by a Licensed Pesticide Applicator. Further, the product is approved as a contraceptive for rodents and must be continually fed, said James Herbert, Neogen CEO and chairman. Whereas the product may have use in some applications, it would face very limited use in the food and agricultural industry where Neogen is focused. We wish the SenesTech team success as they go forward with their plans to commercialize this contraceptive product.
Neogen Corporation develops and markets products dedicated to food and animal safety. The companys Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogens Animal Safety Division is a leader in the development of animal genomics along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.
###